Illumina, Inc.
Illumina, Inc. (ILMN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ILMN · as of Jun 8, 2026
Key Statistics
Explore Illumina, Inc. Data
ilmn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 50 · Buy rate: 50.0%
The ILMN analyst consensus is Buy, based on ratings from 50 Wall Street analysts over the past 3 months. The average 12-month price target is $151.40, representing -6.73% downside from the current price of $162.32.
Competitors & Peers
ilmn competitorsILMN
DGX
GMAB
HOLX
ICLR
LHStock Performance
Full HistoryAbout Illumina, Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solution…
what is illumina, inc. · ilmn stock overview · illumina, inc. company profile · who is illumina, inc. ceo · ilmn NASDAQ · illumina, inc. headquarters · illumina, inc. business segments
About Stock Overview & Key Data
Illumina, Inc. (ILMN) is a Healthcare company in the Medical - Diagnostics & Research industry, listed on NASDAQ since Jul 28, 2000. As of the latest trading session, ILMN stock price is $162.32, with a market capitalization of $24.6B. The stock has returned +91.01% over the past 12 months and +23.76% year-to-date.
According to 50 Wall Street analysts, the consensus rating for Illumina, Inc. stock is Buy, with an average 12-month price target of $151.40. In fiscal year 2025, Illumina, Inc. reported revenue of $4.3B and net income of $850.0M. For detailed data — including Illumina, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Illumina, Inc. (ILMN) stock price is $162.32. The stock is traded on NASDAQ under the ticker symbol ILMN. The 52-week range is $81.76 – $172.49.